1+ day, 22+ hour ago   (242+ words) The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise. Bristol Myers won its latest approval based on Phase 3 data showing the Zenbexus combination was superior…...

2+ day, 22+ hour ago   (349+ words) The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing. EGFR exon 20 insertion mutations are present in only a small fraction of lung cancers. EGFR mutations broadly account for…...

2+ day, 23+ hour ago   (367+ words) Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications. Sangamo is a decades-old company that was once on the cutting edge of…...

3+ day, 23+ hour ago   (356+ words) Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine. Lilly is seeking the help of courts, regulators and law enforcement agencies at…...

4+ day, 3+ hour ago   (416+ words) Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases. Boulevard Bio, a new startup co-founded by pioneering autoimmune disease researcher Georg…...

4+ day, 22+ hour ago   (246+ words) Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines. The CEO who helped guide development of the top-selling cell therapy for multiple myeloma will take the reins of…...

5+ day, 32+ min ago   (508+ words) Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications. Dupixent, a drug cleared for eczema and many other autoimmune conditions, is one of the world’s best-selling medicines. But…...

5+ day, 1+ hour ago   (328+ words) Epicrispr Biotechnologies has raised another $90 million to accelerate development of a first-of-its-kind treatment for a rare genetic muscle disorder. The Series C round announced Tuesday “marks a pivotal milestone for Epicrispr as we advance EPI-321 and the next generation of…...

5+ day, 1+ hour ago   (495+ words) The executive order aims to split the MMR vaccine into three separate shots and revive a court-stalled attempt to narrow the immunization schedule. President Donald Trump has revived his administration’s attempts to alter the U.S.’ longstanding childhood immunization schedule, signing…...

5+ day, 2+ hour ago   (422+ words) The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker. Vaderis Therapeutics, a biotechnology firm working on a treatment for a rare, inherited…...